A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose

Yoshimi Tsuda, Christopher J. Parkins, Patrizia Caposio, Friederike Feldmann, Sara Botto, Susan Ball, Ilhem Messaoudi, Luka Cicin-Sain, Heinz Feldmann, Michael A. Jarvis

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Ebola virus (Zaire ebolavirus; EBOV) is a highly lethal hemorrhagic disease virus that most recently was responsible for two independent 2014 outbreaks in multiple countries in Western Africa, and the Democratic Republic of the Congo, respectively. Herein, we show that a cytomegalovirus (CMV)-based vaccine provides durable protective immunity from Ebola virus following a single vaccine dose. This study has implications for human vaccination against ebolaviruses, as well as for development of a 'disseminating' vaccine to target these viruses in wild African great apes.

Original languageEnglish (US)
Pages (from-to)2261-2266
Number of pages6
JournalVaccine
Volume33
Issue number19
DOIs
StatePublished - 2015

Fingerprint

Zaire Ebola virus
Cytomegalovirus Vaccines
Ebolavirus
Cytomegalovirus
vaccines
viruses
Democratic Republic of the Congo
vaccine development
Pongidae
dosage
Western Africa
Vaccines
immunity
vaccination
Hominidae
Virus Diseases
Disease Outbreaks
Immunity
Vaccination
Viruses

Keywords

  • Cytomegalovirus
  • Disseminating
  • Durable
  • Ebola
  • Ebolavirus
  • Great apes
  • Mouse
  • Protection
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose. / Tsuda, Yoshimi; Parkins, Christopher J.; Caposio, Patrizia; Feldmann, Friederike; Botto, Sara; Ball, Susan; Messaoudi, Ilhem; Cicin-Sain, Luka; Feldmann, Heinz; Jarvis, Michael A.

In: Vaccine, Vol. 33, No. 19, 2015, p. 2261-2266.

Research output: Contribution to journalArticle

Tsuda, Y, Parkins, CJ, Caposio, P, Feldmann, F, Botto, S, Ball, S, Messaoudi, I, Cicin-Sain, L, Feldmann, H & Jarvis, MA 2015, 'A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose', Vaccine, vol. 33, no. 19, pp. 2261-2266. https://doi.org/10.1016/j.vaccine.2015.03.029
Tsuda, Yoshimi ; Parkins, Christopher J. ; Caposio, Patrizia ; Feldmann, Friederike ; Botto, Sara ; Ball, Susan ; Messaoudi, Ilhem ; Cicin-Sain, Luka ; Feldmann, Heinz ; Jarvis, Michael A. / A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose. In: Vaccine. 2015 ; Vol. 33, No. 19. pp. 2261-2266.
@article{d5869481563c4d0bbe3402263baea7a3,
title = "A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose",
abstract = "Ebola virus (Zaire ebolavirus; EBOV) is a highly lethal hemorrhagic disease virus that most recently was responsible for two independent 2014 outbreaks in multiple countries in Western Africa, and the Democratic Republic of the Congo, respectively. Herein, we show that a cytomegalovirus (CMV)-based vaccine provides durable protective immunity from Ebola virus following a single vaccine dose. This study has implications for human vaccination against ebolaviruses, as well as for development of a 'disseminating' vaccine to target these viruses in wild African great apes.",
keywords = "Cytomegalovirus, Disseminating, Durable, Ebola, Ebolavirus, Great apes, Mouse, Protection, Vaccine",
author = "Yoshimi Tsuda and Parkins, {Christopher J.} and Patrizia Caposio and Friederike Feldmann and Sara Botto and Susan Ball and Ilhem Messaoudi and Luka Cicin-Sain and Heinz Feldmann and Jarvis, {Michael A.}",
year = "2015",
doi = "10.1016/j.vaccine.2015.03.029",
language = "English (US)",
volume = "33",
pages = "2261--2266",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "19",

}

TY - JOUR

T1 - A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose

AU - Tsuda, Yoshimi

AU - Parkins, Christopher J.

AU - Caposio, Patrizia

AU - Feldmann, Friederike

AU - Botto, Sara

AU - Ball, Susan

AU - Messaoudi, Ilhem

AU - Cicin-Sain, Luka

AU - Feldmann, Heinz

AU - Jarvis, Michael A.

PY - 2015

Y1 - 2015

N2 - Ebola virus (Zaire ebolavirus; EBOV) is a highly lethal hemorrhagic disease virus that most recently was responsible for two independent 2014 outbreaks in multiple countries in Western Africa, and the Democratic Republic of the Congo, respectively. Herein, we show that a cytomegalovirus (CMV)-based vaccine provides durable protective immunity from Ebola virus following a single vaccine dose. This study has implications for human vaccination against ebolaviruses, as well as for development of a 'disseminating' vaccine to target these viruses in wild African great apes.

AB - Ebola virus (Zaire ebolavirus; EBOV) is a highly lethal hemorrhagic disease virus that most recently was responsible for two independent 2014 outbreaks in multiple countries in Western Africa, and the Democratic Republic of the Congo, respectively. Herein, we show that a cytomegalovirus (CMV)-based vaccine provides durable protective immunity from Ebola virus following a single vaccine dose. This study has implications for human vaccination against ebolaviruses, as well as for development of a 'disseminating' vaccine to target these viruses in wild African great apes.

KW - Cytomegalovirus

KW - Disseminating

KW - Durable

KW - Ebola

KW - Ebolavirus

KW - Great apes

KW - Mouse

KW - Protection

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84929574655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929574655&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2015.03.029

DO - 10.1016/j.vaccine.2015.03.029

M3 - Article

C2 - 25820063

AN - SCOPUS:84929574655

VL - 33

SP - 2261

EP - 2266

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 19

ER -